达格列净联合沙库巴曲缬沙坦钠片对急性心肌梗死急诊介入治疗后心力衰竭患者的疗效

Efficacy of Dapagliflozin Combined with Sacubitril Valsartan Sodium Tablets in Patients with Heart Failure after Emergency Interventional Therapy of Acute Myocardial Infarction

目的:观察达格列净联合沙库巴曲缬沙坦钠片对急性心肌梗死(acute myocardial infarction,AMI)急诊介入治疗后心力衰竭(heart failure,HF)患者的疗效。方法:将鹰潭市人民医院2021年1月—2022年1月收治的AMI急诊介入治疗后HF患者60例用随机数字表法分为两组。对照组予以沙库巴曲缬沙坦钠片治疗,研究组予以达格列净联合沙库巴曲缬沙坦钠片治疗。比较两组心功能指标、生化指标、疗效及不良反应。结果:治疗后研究组N-末端脑钠肽前体(N-terminal pro-brain natriuretic peptide,NT-proBNP)、肌酸激酶同工酶(creatine kinase MB,CK-MB)均低于对照组(P<0.05)。治疗后,研究组左心室收缩末期内径(left ventricular end systolic diameter,LVESD)、左心室舒张末期内径(left ventricular end diastolic diameter,LVEDD)均小于对照组,左室射血分数(left ventricular ejection fraction,LVEF)、心排血量(cardiac output,CO)均高于对照组(P<0.05)。研究组总有效率较对照组高,差异有统计学意义(P<0.05)。研究组不良反应发生率与对照组比较,差异无统计学意义(P>0.05)。结论:AMI急诊介入治疗后HF患者用达格列净联合沙库巴曲缬沙坦钠片治疗,可显著改善患者心功能,提升治疗效果,且不会增加不良反应风险。

Objective:To observe the efficacy of Dapagliflozin combined with Sacubitril Valsartan Sodium Tablets in the treatment of patients with heart failure(HF)after emergency interventional therapy of acute myocardial infarction(AMI).Method:A total of 60 patients with HF after emergency interventional therapy of AMI admitted to Yingtan City People's Hospital from January 2021 to January 2022 were divided into two groups by random number method.The control group was treated with Sacubitril Valsartan Sodium Tablets,and the study group was treated with Dapagliflozin combined with Sacubitril Valsartan Sodium Tablets.The cardiac function indexes,biochemical indexes,efficacy and adverse reactions were compared between the two groups.Result:After treatment,N-terminal pro-brain natriuretic peptide(NT-proBNP),creatine kinase MB(CK-MB)in the study group were lower than those in the control group(P<0.05).After treatment,left ventricular end systolic diameter(LVESD),left ventricular end diastolic diameter(LVEDD)in the study group were smaller than those in the control group,left ventricular ejection fraction(LVEF)and cardiac output(CO)were higher than those in the control group(P<0.05).The total effective rate of the study group was higher than that of the control group,the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the study group and the control group(P>0.05).Conclusion:Dapagliflozin combined with Sacubitril Valsartan Sodium Tablets in the treatment of patients with HF after emergency interventional therapy of AMI can significantly improve patients'cardiac function,enhance the therapeutic effect,and will not increase the risk of adverse reactions.